Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See exactly how DHR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DHR and 80,000+ other tickers.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics…
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.
Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.
Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.